evaluate the pharmaceuticals company zepbound on glp-1 and insurance providers Why Won't Cover Weight Loss Perspectives from employers on the

A separate study published in August 2025 found patients prescribed semaglutide or tirzepatide for Type 2 diabetes had an increased risk of NAION and other optic nerve disorders, but the overall risk was very low

Combination with other agents might allow dose reduction of the GLP-1 component

Using several hormones in low doses and incorporating lifestyle interventions might maximize the clinical effect while minimizing the side effects. Clearly, many patients would find daily injections of hormones preferable to undergoing bariatric surgery, even if these injections would need to be continued in the long-term to keep the weight off

Consult with a Healthcare Professional: Before starting any new supplementation regimen, its wise to consult with a healthcare provider